EGFR and neoplasm: Recently, EGFR has been identified as a driver of oncogenes in NSCLC, because the mutation of activating EGFR kinase domain enhances the activity of EGFR tyrosine kinase, leading to continuous activation of the downstream signal pathway, and then drives tumorigenesis and tumor progression (32).